Alkermes plc (NASDAQ:ALKS) Q3 2022 Earnings Conference Call November 2, 2022 8:00 AM ET
Company Participants
Sandra Coombs - SVP, IR & Corporate Affairs
Richard Pops - CEO
Iain Brown - CFO
Todd Nichols - CCO
Conference Call Participants
Umer Raffat - Evercore ISI
Chris Shibutani - Goldman Sachs
Brandon Folkes - Cantor Fitzgerald
Uy Ear - Mizuho
David Amsellem - Piper Sandler
Marc Goodman - SVB Securities
Jason Gerberry - Bank of America
Operator
Greetings, and welcome to the Alkermes Third Quarter 2022 Financial Results Conference Call. My name is Melissa, and I will be your operator for today's call. [Operator Instructions] Please note that this conference is being recorded.
I'll now turn the call over to Sandra Coombs, Senior Vice President of Investor Relations and Corporate Affairs. Sandy, you may begin.
Sandra Coombs
Good morning. Welcome to the Alkermes plc conference call to discuss our financial results and business update for the quarter ended September 30, 2022, and the proposed separation of Alkermes neuroscience and oncology businesses. With me today are Richard Pops, our CEO; Iain Brown, our CFO; and Todd Nichols, our Chief Commercial Officer.
Before we begin, I encourage everyone to go to the Investors section of alkermes.com to find our press release, related financial tables and reconciliations of the GAAP to non-GAAP financial measures that we'll discuss today. We believe the non-GAAP financial results in conjunction with the GAAP results are useful in understanding the ongoing economics of our business.
Our discussions during this conference call will include forward-looking statements. Actual results could differ materially from these forward-looking statements. Please see Slide 2 of the accompanying presentation, our press release issued this morning and our most recent annual and quarterly reports filed with the SEC for important risk factors that could cause our actual results to differ materially from those expressed or implied in the forward-looking statements. We undertake no obligation to update or revise the information provided on this call or in the accompanying presentation as a result of new information or future results or developments. After our prepared remarks, we'll open the call for Q&A.
Now I'll turn the call over to Richard.
Richard Pops
Thank you, Sandy. Good morning, everyone. So we had a strong third quarter financially and operationally. On the neuroscience side, our commercial portfolio performed well, highlighted by LYBALVI, and we took an important step forward for our next pipeline candidate with our orexin 2 receptor agonist now entering the clinic. After a year in the market, we're confident that LYBALVI has attributes of an important new psychiatric medicine.